12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Erivedge vismodegib: Additional Phase II data

Additional data from the open-label, international Phase II ERIVANCE BCC trial in 104 patients with inoperable advanced BCC showed that once-daily 150 mg oral vismodegib led to a 1-year survival rate of 77.3% in patients with metastatic BCC (n=33) and 93.1% in patients with locally advanced BCC (n=63). Data will be presented at the American Society of...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >